CR2Cancer

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Domain, Function and Classification > Gene Ontology > KEGG and Reactome Pathway

> Domain, Function and Classification

[ TOP ]

Domain

PF00956 Nucleosome assembly protein (NAP)

Function

Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher.

Classification

Class	Modification	Substrate	Product	PubMed
Histone modification	#	#	#	17320507

> Gene Ontology [ TOP ]
Biological Process	GO:0006260 DNA replication GO:0006323 DNA packaging GO:0006333 chromatin assembly or disassembly GO:0006334 nucleosome assembly GO:0006337 nucleosome disassembly GO:0006470 protein dephosphorylation GO:0006473 protein acetylation GO:0006475 internal protein amino acid acetylation GO:0006913 nucleocytoplasmic transport GO:0010608 posttranscriptional regulation of gene expression GO:0010921 regulation of phosphatase activity GO:0016311 dephosphorylation GO:0016570 histone modification GO:0016573 histone acetylation GO:0018205 peptidyl-lysine modification GO:0018393 internal peptidyl-lysine acetylation GO:0018394 peptidyl-lysine acetylation GO:0031056 regulation of histone modification GO:0031057 negative regulation of histone modification GO:0031497 chromatin assembly GO:0031498 chromatin disassembly GO:0032984 macromolecular complex disassembly GO:0032986 protein-DNA complex disassembly GO:0034047 regulation of protein phosphatase type 2A activity GO:0034728 nucleosome organization GO:0035065 regulation of histone acetylation GO:0035067 negative regulation of histone acetylation GO:0035303 regulation of dephosphorylation GO:0035304 regulation of protein dephosphorylation GO:0043241 protein complex disassembly GO:0043487 regulation of RNA stability GO:0043488 regulation of mRNA stability GO:0043523 regulation of neuron apoptotic process GO:0043524 negative regulation of neuron apoptotic process GO:0043543 protein acylation GO:0043666 regulation of phosphoprotein phosphatase activity GO:0051169 nuclear transport GO:0051402 neuron apoptotic process GO:0065004 protein-DNA complex assembly GO:0070997 neuron death GO:0071103 DNA conformation change GO:0071824 protein-DNA complex subunit organization GO:1901214 regulation of neuron death GO:1901215 negative regulation of neuron death GO:1901983 regulation of protein acetylation GO:1901984 negative regulation of protein acetylation GO:1902275 regulation of chromatin organization GO:1905268 negative regulation of chromatin organization GO:2000756 regulation of peptidyl-lysine acetylation GO:2000757 negative regulation of peptidyl-lysine acetylation
Molecular Function	GO:0004857 enzyme inhibitor activity GO:0004864 protein phosphatase inhibitor activity GO:0008601 protein phosphatase type 2A regulator activity GO:0019208 phosphatase regulator activity GO:0019212 phosphatase inhibitor activity GO:0019888 protein phosphatase regulator activity GO:0042393 histone binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-2299718: Condensation of Prophase Chromosomes R-HSA-74160: Gene Expression R-HSA-450520: HuR (ELAVL1) binds and stabilizes mRNA R-HSA-68886: M Phase R-HSA-68875: Mitotic Prophase R-HSA-450531: Regulation of mRNA stability by proteins that bind AU-rich elements

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Mutation landscape in primary tumor tissue from TCGA > Mutation landscape in cancer cell line from CCLE > All mutations from COSMIC database V81 > Variations from text mining

> The Cancer Genome Atlas (TCGA) [ TOP ]

> Cancer Cell Line Encyclopedia (CCLE) [ TOP ]

> Catalogue of Somatic Mutations in Cancer (COSMIC)

[ TOP ]

COSMIC ID	CDS change	AA change	Mutation Type	Anatomical Site
COSM3432898	c.523A>G	p.N175D	Substitution - Missense	Large_intestine
COSM1105699	c.156G>T	p.E52D	Substitution - Missense	Endometrium
COSM3904549	c.702A>T	p.E234D	Substitution - Missense	Breast
COSM1105696	c.90A>C	p.E30D	Substitution - Missense	Endometrium
COSM3904549	c.702A>T	p.E234D	Substitution - Missense	Stomach
COSM1755973	c.300T>A	p.D100E	Substitution - Missense	Urinary_tract
COSM3926255	c.537G>A	p.R179R	Substitution - coding silent	Skin
COSM3432895	c.509C>T	p.S170L	Substitution - Missense	Large_intestine
COSM1460300	c.234delC	p.P79fs*5	Deletion - Frameshift	Large_intestine
COSM5644743	c.5C>T	p.S2L	Substitution - Missense	Oesophagus
COSM384861	c.630T>A	p.D210E	Substitution - Missense	Lung
COSM5702613	c.701A>G	p.E234G	Substitution - Missense	Liver
COSM3904546	c.500C>T	p.T167M	Substitution - Missense	Stomach
COSM5768728	c.424G>T	p.E142*	Substitution - Nonsense	Breast
COSM4447106	c.811-3C>T	p.?	Unknown	Skin
COSM4725124	c.565T>C	p.F189L	Substitution - Missense	Large_intestine
COSM1105693	c.83A>C	p.Q28P	Substitution - Missense	Endometrium
COSM4451893	c.107A>T	p.D36V	Substitution - Missense	Skin
COSM3327566	c.748G>A	p.E250K	Substitution - Missense	Skin
COSM5230004	c.696_698delAGA	p.E234delE	Deletion - In frame	Breast
COSM1460298	c.190C>T	p.R64C	Substitution - Missense	Large_intestine
COSM4854878	c.132-1G>C	p.?	Unknown	Cervix
COSM1460308	c.695G>A	p.G232E	Substitution - Missense	Large_intestine
COSM1105702	c.257T>G	p.F86C	Substitution - Missense	Endometrium
COSM1460302	c.469G>T	p.E157*	Substitution - Nonsense	Large_intestine
COSM1105711	c.512G>T	p.S171I	Substitution - Missense	Endometrium
COSM3769723	c.492+2T>A	p.?	Unknown	Soft_tissue
COSM3904543	c.368G>C	p.R123T	Substitution - Missense	Stomach
COSM1292801	c.641C>T	p.P214L	Substitution - Missense	Haematopoietic_and_lymphoid_tissue
COSM1755973	c.300T>A	p.D100E	Substitution - Missense	Urinary_tract
COSM5422540	c.672T>C	p.D224D	Substitution - coding silent	Prostate
COSM5702616	c.775_776insA	p.D260fs*2	Insertion - Frameshift	Ovary
COSM1460306	c.533G>A	p.S178N	Substitution - Missense	Large_intestine
COSM1105705	c.274+2T>C	p.?	Unknown	Endometrium
COSM1265318	c.501G>T	p.T167T	Substitution - coding silent	Stomach
COSM5410490	c.64G>A	p.E22K	Substitution - Missense	Skin
COSM3432895	c.509C>T	p.S170L	Substitution - Missense	Stomach
COSM1460304	c.518C>T	p.T173M	Substitution - Missense	Large_intestine
COSM4840743	c.604G>T	p.D202Y	Substitution - Missense	Cervix
COSM3654708	c.395C>T	p.P132L	Substitution - Missense	Skin
COSM1265320	c.636T>C	p.I212I	Substitution - coding silent	Stomach
COSM3904540	c.313C>T	p.H105Y	Substitution - Missense	Stomach
COSM1105708	c.469G>A	p.E157K	Substitution - Missense	Endometrium
COSM3654711	c.433C>T	p.L145L	Substitution - coding silent	Skin
COSM4725121	c.191G>A	p.R64H	Substitution - Missense	Large_intestine
COSM4980589	c.458C>T	p.S153L	Substitution - Missense	Oesophagus

> Text Mining based Variations

[ TOP ]

PMID	Variation	Cancer	Evidence
23210573	Mutation	Acute Lymphoblastic Leukemia	Our RT-nPCR assay had a positive detection rate of 35.15% (90/256) for the 10 fusion genes. BCR-ABL1, FUS-ERG, MLL-AF4, ETV6-RUNX1, E2A-PBX1, dupMLL, MLL-AF10, MLL-ENL, SET-NUP214 and SIL-TAL1 were detected in 36 (14.06%), 14 (5.47%), 14 (5.47%), four (1.56%), four (1.56%), five (1.95%), four (1.56%), two (0.78%), two (0.78%) and five patients (1.95%), respectively.
23114116	Mutation	T Acute Lymphoblastic Leukemia	The results showed that 6 out of 58 T-ALL cases (10.3%) were detected to have the SET-NUP214 fusion gene by RT-PCR.
22169284	Mutation	Leukemia; Lymphoma	The purpose of this study was to analyze the gene rearrangement pattern of immunoglobulin and T-cell receptor (Ig/TR) and its clinical characteristics in three children with SET-NUP214 fusion gene positive leukemia/lymphoma. The transcript of SET-NUP214 fusion gene was detected by RT-nested PCR.
22075511	Mutation	T Acute Lymphoblastic Leukemia	Here, we describe a novel case of T-ALL associated with a mediastinal mass and a SET-NUP214 rearrangement, which was masked by a complex karyotype at the time of initial diagnosis. Using multiplex reverse transcriptase-polymerase chain reaction analysis, we detected a cryptic SET-NUP214 rearrangement in our patient.
21880637	Mutation	T Acute Lymphoblastic Leukemia	We analyzed the incidence and prognostic value of PHF6 mutations in 96 Chinese patients with T-cell acute lymphoblastic leukemia.. NOTCH1 mutations, FBXW7 mutations, WT1 mutations, JAK1 mutations, SIL-TAL1 fusions, SET-NUP214 fusions and CALM-AF10 fusions were present in 44/96 (45.8%), 9/96 (9.4%), 4/96 (4.1%), 3/49 (6.1%), 9/48 (18.8%), 3/48 (6.3%) and 0/48 (0%) of patients, respectively.
21720744	Mutation	T Acute Lymphoblastic Leukemia	Four cases (10%) of SET-NUP214 translocation were identified in our study.
20682390	Mutation	acute undifferentiated Leukemia	Herein we present a novel case of acute undifferentiated leukemia with SET-NUP214 rearrangement due to the cryptic deletion of the 9q34 region producing two different types of fusion transcripts by alternative splicing and molecular characterization of the fusion transcripts by fluorescence in situ hybridization, reverse transcriptase-polymerase chain reaction, and array comparative genomic hybridization analyses.
20494936	Mutation	Acute Lymphoblastic Leukemia	We demonstrated that high expression of miR-196b is not unique to MLL-rearranged acute lymphoblastic leukemia but also occurs in patients with T-cell acute lymphoblastic leukemia patients carrying CALM-AF10, SET-NUP214 and inversion of chromosome 7.
20417863	Mutation	B Acute Lymphoblastic Leukemia	The results demonstrate cryptic deletions of 9q34 involving SET, PKN3, NUP188, ABL1, and NUP214 in three of the samples. The smallest deletion resulted in the likely juxtaposition of the SET and NUP214 genes.

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Post-translational modification (PTM)

> Post-translational modification (PTM)

[ TOP ]

Filter By:

Uniprot ID	Position	Amino Acid	Description	Upstream Enzyme	Affected By Mutation	Amino Acid Sequence Variant
Q01105	7	S	Phosphoserine	-	No	None detected
Q01105	28	S	Phosphoserine	-	No	None detected
Q01105	63	S	Phosphoserine	-	No	None detected
Q01105	68	K	N6-acetyllysine	-	No	None detected
Q01105	146	Y	Phosphotyrosine	-	No	None detected
Q01105	150	K	N6-acetyllysine	-	No	None detected
Q01105	172	K	N6-acetyllysine	-	No	None detected

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Expression analysis in primary tumor tissue from TCGA > Expression level in cancer cell line from CCLE > Expression level in human normal tissue from HPA > Text mining based expression change

> The Cancer Genome Atlas (TCGA)

[ TOP ]

Differential expression analysis for cancers with more than 10 normal samples

Cancer	Full Name	# N	# T	Median (N)	Median (T)	LogFC	Adj. P	Status
BLCA	Bladder urothelial carcinoma	19	408	8.159	8.413	0.19	0.181	NS
BRCA	Breast invasive carcinoma	112	1100	8.058	8.536	0.503	1.43e-29	NS
CESC	Cervical and endocervical cancers	3	306	8.245	8.598	NA	NA	NA
COAD	Colon adenocarcinoma	41	459	7.664	8.552	0.852	8.2e-24	Over
ESCA	Esophageal carcinoma	11	185	7.293	8.001	0.71	7.79e-05	Over
GBM	Glioblastoma multiforme	5	166	7.765	8.103	NA	NA	NA
HNSC	Head and Neck squamous cell carcinoma	44	522	7.829	8.26	0.436	5.6e-09	NS
KIRC	Kidney renal clear cell carcinoma	72	534	8.024	7.976	-0.079	0.0962	NS
KIRP	Kidney renal papillary cell carcinoma	32	291	7.728	7.987	0.247	0.00016	NS
LAML	Acute Myeloid Leukemia	0	173	NA	8.461	NA	NA	NA
LGG	Brain Lower Grade Glioma	0	530	NA	8.158	NA	NA	NA
LIHC	Liver hepatocellular carcinoma	50	373	6.959	7.013	0.076	0.32	NS
LUAD	Lung adenocarcinoma	59	517	7.762	8.027	0.262	0.000126	NS
LUSC	Lung squamous cell carcinoma	51	501	7.681	8.462	0.775	1.15e-23	Over
OV	Ovarian serous cystadenocarcinoma	0	307	NA	8.098	NA	NA	NA
PAAD	Pancreatic adenocarcinoma	4	179	7.917	7.909	NA	NA	NA
PCPG	Pheochromocytoma and Paraganglioma	3	184	7.519	7.565	NA	NA	NA
PRAD	Prostate adenocarcinoma	52	498	7.85	8.136	0.268	2.36e-07	NS
READ	Rectum adenocarcinoma	10	167	7.829	8.468	0.571	0.00501	NS
SARC	Sarcoma	2	263	7.799	7.956	NA	NA	NA
SKCM	Skin Cutaneous Melanoma	1	472	8.787	8.145	NA	NA	NA
STAD	Stomach adenocarcinoma	35	415	7.322	7.947	0.656	5.01e-12	Over
TGCT	Testicular Germ Cell Tumors	0	156	NA	9.126	NA	NA	NA
THCA	Thyroid carcinoma	59	509	8.03	8.191	0.135	0.00122	NS
THYM	Thymoma	2	120	8.293	8.686	NA	NA	NA
UCEC	Uterine Corpus Endometrial Carcinoma	35	546	8.242	8.476	0.246	0.01	NS

> Cancer Cell Line Encyclopedia (CCLE)

[ TOP ]

Tissue	Cell Line	Expression Level (Microarray)
Autonomic ganglia	CHP126	12.9
Autonomic ganglia	CHP212	12.5
Autonomic ganglia	IMR32	12.9
Autonomic ganglia	KELLY	12.5
Autonomic ganglia	KPNRTBM1	12.7
Autonomic ganglia	KPNSI9S	12
Autonomic ganglia	KPNYN	12.7
Autonomic ganglia	MHHNB11	12.4
Autonomic ganglia	NB1	12.9
Autonomic ganglia	NH6	12.4
Autonomic ganglia	SHSY5Y	12.3
Autonomic ganglia	SIMA	12.9
Autonomic ganglia	SKNAS	12.2
Autonomic ganglia	SKNBE2	12.6
Autonomic ganglia	SKNDZ	12.7
Autonomic ganglia	SKNFI	12
Autonomic ganglia	SKNSH	12
Biliary tract	HUCCT1	11.9
Biliary tract	HUH28	11.7
Biliary tract	SNU1079	12
Biliary tract	SNU1196	12.6
Biliary tract	SNU245	12.3
Biliary tract	SNU308	12.6
Biliary tract	SNU478	12.2
Bone	143B	12.5
Bone	A673	12.7
Bone	CADOES1	12.9
Bone	CAL78	11.9
Bone	G292CLONEA141B1	12.1
Bone	HOS	12.5
Bone	HS706T	11.4
Bone	HS737T	11.3
Bone	HS819T	11
Bone	HS821T	11.3
Bone	HS822T	10.9
Bone	HS863T	11.4
Bone	HS870T	11.5
Bone	HS888T	12
Bone	MG63	12.1
Bone	MHHES1	12.6
Bone	OUMS27	11.5
Bone	RDES	12.8
Bone	SJSA1	11.6
Bone	SKES1	13.3
Bone	SKNMC	12.8
Bone	SW1353	11.9
Bone	T173	10.9
Bone	TC71	12.5
Bone	U2OS	11.6
Breast	AU565	12.2
Breast	BT20	12.8
Breast	BT474	13.1
Breast	BT483	12.4
Breast	BT549	12.5
Breast	CAL120	12.6
Breast	CAL148	12.9
Breast	CAL51	12.8
Breast	CAL851	12.5
Breast	CAMA1	12.3
Breast	DU4475	12.3
Breast	EFM192A	12.2
Breast	EFM19	12.6
Breast	EVSAT	12.4
Breast	HCC1143	12.2
Breast	HCC1187	12.6
Breast	HCC1395	11.3
Breast	HCC1419	12.3
Breast	HCC1428	12.8
Breast	HCC1500	12.6
Breast	HCC1569	12.3
Breast	HCC1599	13.2
Breast	HCC1806	11.7
Breast	HCC1937	12.4
Breast	HCC1954	12.1
Breast	HCC202	12.2
Breast	HCC2157	12.5
Breast	HCC2218	12.3
Breast	HCC38	12
Breast	HCC70	11.8
Breast	HDQP1	12.4
Breast	HMC18	12.4
Breast	HS274T	11.2
Breast	HS281T	11.7
Breast	HS343T	11.7
Breast	HS578T	10.9
Breast	HS606T	11.3
Breast	HS739T	11.4
Breast	HS742T	11.1
Breast	JIMT1	12.7
Breast	KPL1	12.3
Breast	MCF7	12.1
Breast	MDAMB134VI	12.7
Breast	MDAMB157	11.8
Breast	MDAMB175VII	12.3
Breast	MDAMB231	12.2
Breast	MDAMB361	12.5
Breast	MDAMB415	11.2
Breast	MDAMB436	12.3
Breast	MDAMB453	12.2
Breast	MDAMB468	12.2
Breast	SKBR3	12.5
Breast	T47D	12.1
Breast	UACC812	11.1
Breast	UACC893	12.1
Breast	YMB1	12
Breast	ZR751	12.3
Breast	ZR7530	12.1
Central nervous system	1321N1	12.1
Central nervous system	42MGBA	11.3
Central nervous system	8MGBA	11.7
Central nervous system	A172	12.5
Central nervous system	AM38	12.3
Central nervous system	BECKER	12
Central nervous system	CAS1	12
Central nervous system	CCFSTTG1	11.9
Central nervous system	D283MED	12.9
Central nervous system	D341MED	12.7
Central nervous system	DAOY	12.6
Central nervous system	DBTRG05MG	12.2
Central nervous system	DKMG	11.6
Central nervous system	GAMG	11.7
Central nervous system	GB1	12.3
Central nervous system	GI1	12.3
Central nervous system	GMS10	11.8
Central nervous system	GOS3	12.1
Central nervous system	H4	11.9
Central nervous system	HS683	11.8
Central nervous system	KALS1	12.2
Central nervous system	KG1C	11.9
Central nervous system	KNS42	12.3
Central nervous system	KNS60	11.6
Central nervous system	KNS81	12
Central nervous system	KS1	11.6
Central nervous system	LN18	11.1
Central nervous system	LN229	11.9
Central nervous system	M059K	12
Central nervous system	MOGGCCM	12.2
Central nervous system	MOGGUVW	11.7
Central nervous system	NMCG1	11.8
Central nervous system	ONS76	11.1
Central nervous system	SF126	11.5
Central nervous system	SF295	12
Central nervous system	SNB19	11.8
Central nervous system	SNU1105	12
Central nervous system	SNU201	12
Central nervous system	SNU466	11.7
Central nervous system	SNU489	12.4
Central nervous system	SNU626	12.3
Central nervous system	SNU738	12.3
Central nervous system	SW1088	12
Central nervous system	SW1783	11.9
Central nervous system	T98G	11.7
Central nervous system	TM31	11.8
Central nervous system	U118MG	11.8
Central nervous system	U138MG	11.6
Central nervous system	U251MG	11.6
Central nervous system	U87MG	11.9
Central nervous system	YH13	12.1
Central nervous system	YKG1	12
Endometrium	AN3CA	12.4
Endometrium	COLO684	12.3
Endometrium	EFE184	12.3
Endometrium	EN	11.9
Endometrium	ESS1	11.7
Endometrium	HEC108	11.5
Endometrium	HEC151	11.8
Endometrium	HEC1A	12.5
Endometrium	HEC1B	12.3
Endometrium	HEC251	12.3
Endometrium	HEC265	12.1
Endometrium	HEC50B	11.8
Endometrium	HEC59	12.3
Endometrium	HEC6	11.6
Endometrium	ISHIKAWAHERAKLIO02ER	12.6
Endometrium	JHUEM1	12.4
Endometrium	JHUEM2	12.4
Endometrium	JHUEM3	12.2
Endometrium	KLE	11.3
Endometrium	MFE280	12.6
Endometrium	MFE296	12.4
Endometrium	MFE319	12
Endometrium	RL952	12.4
Endometrium	SNGM	12.3
Endometrium	SNU1077	11.6
Endometrium	SNU685	12.3
Endometrium	TEN	11.7
Haematopoietic and lymphoid	697	12.9
Haematopoietic and lymphoid	A3KAW	12.1
Haematopoietic and lymphoid	A4FUK	12.2
Haematopoietic and lymphoid	ALLSIL	12.8
Haematopoietic and lymphoid	AML193	12.2
Haematopoietic and lymphoid	AMO1	12.5
Haematopoietic and lymphoid	BCP1	12.3
Haematopoietic and lymphoid	BDCM	12.2
Haematopoietic and lymphoid	BL41	13
Haematopoietic and lymphoid	BL70	12.8
Haematopoietic and lymphoid	BV173	12.2
Haematopoietic and lymphoid	CA46	12.4
Haematopoietic and lymphoid	CI1	12.5
Haematopoietic and lymphoid	CMK115	12.5
Haematopoietic and lymphoid	CMK86	12.9
Haematopoietic and lymphoid	CMK	12.5
Haematopoietic and lymphoid	CMLT1	12.9
Haematopoietic and lymphoid	COLO775	12.9
Haematopoietic and lymphoid	DAUDI	12.4
Haematopoietic and lymphoid	DB	12.6
Haematopoietic and lymphoid	DEL	11.7
Haematopoietic and lymphoid	DND41	12.5
Haematopoietic and lymphoid	DOHH2	12.7
Haematopoietic and lymphoid	EB1	12.5
Haematopoietic and lymphoid	EB2	12.1
Haematopoietic and lymphoid	EHEB	12.6
Haematopoietic and lymphoid	EJM	12
Haematopoietic and lymphoid	EM2	12.2
Haematopoietic and lymphoid	EOL1	13
Haematopoietic and lymphoid	F36P	12.7
Haematopoietic and lymphoid	GA10	13.1
Haematopoietic and lymphoid	GDM1	12.7
Haematopoietic and lymphoid	GRANTA519	12.8
Haematopoietic and lymphoid	HDLM2	12.4
Haematopoietic and lymphoid	HDMYZ	11.7
Haematopoietic and lymphoid	HEL9217	12.3
Haematopoietic and lymphoid	HEL	12.4
Haematopoietic and lymphoid	HH	12.7
Haematopoietic and lymphoid	HL60	12.7
Haematopoietic and lymphoid	HPBALL	12.7
Haematopoietic and lymphoid	HS604T	11.3
Haematopoietic and lymphoid	HS611T	12.2
Haematopoietic and lymphoid	HS616T	11.3
Haematopoietic and lymphoid	HS751T	11.5
Haematopoietic and lymphoid	HT	12.4
Haematopoietic and lymphoid	HTK	12.7
Haematopoietic and lymphoid	HUNS1	12.2
Haematopoietic and lymphoid	HUT102	11.6
Haematopoietic and lymphoid	HUT78	12.3
Haematopoietic and lymphoid	JEKO1	12.9
Haematopoietic and lymphoid	JK1	12.4
Haematopoietic and lymphoid	JM1	12.9
Haematopoietic and lymphoid	JURKAT	12.8
Haematopoietic and lymphoid	JURLMK1	12.1
Haematopoietic and lymphoid	JVM2	12.9
Haematopoietic and lymphoid	JVM3	12.8
Haematopoietic and lymphoid	K562	12.7
Haematopoietic and lymphoid	KARPAS299	12.1
Haematopoietic and lymphoid	KARPAS422	12.3
Haematopoietic and lymphoid	KARPAS620	12.4
Haematopoietic and lymphoid	KASUMI1	12.7
Haematopoietic and lymphoid	KASUMI2	12.9
Haematopoietic and lymphoid	KASUMI6	12.8
Haematopoietic and lymphoid	KCL22	12.4
Haematopoietic and lymphoid	KE37	12.9
Haematopoietic and lymphoid	KE97	12
Haematopoietic and lymphoid	KG1	12.4
Haematopoietic and lymphoid	KHM1B	11
Haematopoietic and lymphoid	KIJK	12.4
Haematopoietic and lymphoid	KMH2	12.7
Haematopoietic and lymphoid	KMM1	12.5
Haematopoietic and lymphoid	KMS11	12.4
Haematopoietic and lymphoid	KMS12BM	12.7
Haematopoietic and lymphoid	KMS18	12.2
Haematopoietic and lymphoid	KMS20	12.4
Haematopoietic and lymphoid	KMS21BM	11.7
Haematopoietic and lymphoid	KMS26	12.1
Haematopoietic and lymphoid	KMS27	11.6
Haematopoietic and lymphoid	KMS28BM	12.1
Haematopoietic and lymphoid	KMS34	12.1
Haematopoietic and lymphoid	KO52	12.2
Haematopoietic and lymphoid	KOPN8	12.8
Haematopoietic and lymphoid	KU812	12.3
Haematopoietic and lymphoid	KYO1	11.3
Haematopoietic and lymphoid	L1236	12.4
Haematopoietic and lymphoid	L363	11.8
Haematopoietic and lymphoid	L428	13.1
Haematopoietic and lymphoid	L540	11.9
Haematopoietic and lymphoid	LAMA84	12.1
Haematopoietic and lymphoid	LOUCY	11.8
Haematopoietic and lymphoid	LP1	12
Haematopoietic and lymphoid	M07E	12.8
Haematopoietic and lymphoid	MC116	12.7
Haematopoietic and lymphoid	ME1	11.9
Haematopoietic and lymphoid	MEC1	13.2
Haematopoietic and lymphoid	MEC2	12.9
Haematopoietic and lymphoid	MEG01	11.9
Haematopoietic and lymphoid	MHHCALL2	12.8
Haematopoietic and lymphoid	MHHCALL3	13.1
Haematopoietic and lymphoid	MHHCALL4	13
Haematopoietic and lymphoid	MINO	12.5
Haematopoietic and lymphoid	MJ	12.6
Haematopoietic and lymphoid	MM1S	12.4
Haematopoietic and lymphoid	MOLM13	12.5
Haematopoietic and lymphoid	MOLM16	12.5
Haematopoietic and lymphoid	MOLM6	12.6
Haematopoietic and lymphoid	MOLP2	11.8
Haematopoietic and lymphoid	MOLP8	12.5
Haematopoietic and lymphoid	MOLT13	12.9
Haematopoietic and lymphoid	MOLT16	12.8
Haematopoietic and lymphoid	MOLT4	12.5
Haematopoietic and lymphoid	MONOMAC1	12.5
Haematopoietic and lymphoid	MONOMAC6	12.8
Haematopoietic and lymphoid	MOTN1	12.4
Haematopoietic and lymphoid	MUTZ5	13.1
Haematopoietic and lymphoid	MV411	12.7
Haematopoietic and lymphoid	NALM19	12.9
Haematopoietic and lymphoid	NALM1	12.9
Haematopoietic and lymphoid	NALM6	12.9
Haematopoietic and lymphoid	NAMALWA	13
Haematopoietic and lymphoid	NB4	12.6
Haematopoietic and lymphoid	NCIH929	11.8
Haematopoietic and lymphoid	NCO2	12.4
Haematopoietic and lymphoid	NOMO1	12.3
Haematopoietic and lymphoid	NUDHL1	12.2
Haematopoietic and lymphoid	NUDUL1	13.1
Haematopoietic and lymphoid	OCIAML2	12.5
Haematopoietic and lymphoid	OCIAML3	12.6
Haematopoietic and lymphoid	OCIAML5	12.8
Haematopoietic and lymphoid	OCILY10	12.5
Haematopoietic and lymphoid	OCILY19	12.6
Haematopoietic and lymphoid	OCILY3	13.3
Haematopoietic and lymphoid	OCIM1	12.2
Haematopoietic and lymphoid	OPM2	12.1
Haematopoietic and lymphoid	P12ICHIKAWA	12.7
Haematopoietic and lymphoid	P31FUJ	12.1
Haematopoietic and lymphoid	P3HR1	12.4
Haematopoietic and lymphoid	PCM6	12.1
Haematopoietic and lymphoid	PEER	11.9
Haematopoietic and lymphoid	PF382	12.6
Haematopoietic and lymphoid	PFEIFFER	12.8
Haematopoietic and lymphoid	PL21	12.5
Haematopoietic and lymphoid	RAJI	12.5
Haematopoietic and lymphoid	RCHACV	13.2
Haematopoietic and lymphoid	REC1	13
Haematopoietic and lymphoid	REH	12.8
Haematopoietic and lymphoid	RI1	12.9
Haematopoietic and lymphoid	RL	12.4
Haematopoietic and lymphoid	RPMI8226	12.4
Haematopoietic and lymphoid	RPMI8402	13.1
Haematopoietic and lymphoid	RS411	12.6
Haematopoietic and lymphoid	SEM	12.6
Haematopoietic and lymphoid	SET2	12.4
Haematopoietic and lymphoid	SIGM5	12.5
Haematopoietic and lymphoid	SKM1	12.5
Haematopoietic and lymphoid	SKMM2	12.4
Haematopoietic and lymphoid	SR786	11.1
Haematopoietic and lymphoid	ST486	12.8
Haematopoietic and lymphoid	SUDHL10	12.6
Haematopoietic and lymphoid	SUDHL1	12.2
Haematopoietic and lymphoid	SUDHL4	12.7
Haematopoietic and lymphoid	SUDHL5	12.9
Haematopoietic and lymphoid	SUDHL6	12.7
Haematopoietic and lymphoid	SUDHL8	12.3
Haematopoietic and lymphoid	SUPB15	12.5
Haematopoietic and lymphoid	SUPHD1	12.4
Haematopoietic and lymphoid	SUPM2	11.7
Haematopoietic and lymphoid	SUPT11	12.7
Haematopoietic and lymphoid	SUPT1	12.4
Haematopoietic and lymphoid	TALL1	12.4
Haematopoietic and lymphoid	TF1	12.6
Haematopoietic and lymphoid	THP1	11.9
Haematopoietic and lymphoid	TO175T	11.4
Haematopoietic and lymphoid	TOLEDO	12.5
Haematopoietic and lymphoid	U266B1	12.7
Haematopoietic and lymphoid	U937	12
Haematopoietic and lymphoid	UT7	12.5
Haematopoietic and lymphoid	WSUDLCL2	12.5
Kidney	769P	12.4
Kidney	786O	12.5
Kidney	A498	12.3
Kidney	A704	11.5
Kidney	ACHN	11.9
Kidney	BFTC909	11.9
Kidney	CAKI1	11.3
Kidney	CAKI2	12
Kidney	CAL54	12.6
Kidney	KMRC1	12
Kidney	KMRC20	11.8
Kidney	KMRC2	12.4
Kidney	KMRC3	11.5
Kidney	OSRC2	11.4
Kidney	RCC10RGB	11.9
Kidney	SNU1272	12.1
Kidney	SNU349	11.2
Kidney	TUHR10TKB	12.2
Kidney	TUHR14TKB	12
Kidney	TUHR4TKB	11.8
Kidney	VMRCRCW	11.9
Kidney	VMRCRCZ	11.4
Large intestine	C2BBE1	12.6
Large intestine	CCK81	12.4
Large intestine	CL11	12.8
Large intestine	CL14	12.7
Large intestine	CL34	12.6
Large intestine	CL40	12.4
Large intestine	COLO205	12.1
Large intestine	COLO320	13.2
Large intestine	COLO678	12.3
Large intestine	CW2	12
Large intestine	DLD1	12.6
Large intestine	GP2D	12.6
Large intestine	HCC56	12.4
Large intestine	HCT116	12.4
Large intestine	HCT15	12.7
Large intestine	HS675T	11.3
Large intestine	HS698T	11.5
Large intestine	HT115	12.5
Large intestine	HT29	12.6
Large intestine	HT55	12.9
Large intestine	KM12	12.6
Large intestine	LOVO	11.9
Large intestine	LS1034	12.3
Large intestine	LS123	12.6
Large intestine	LS180	12.1
Large intestine	LS411N	11.8
Large intestine	LS513	12.8
Large intestine	MDST8	12.4
Large intestine	NCIH508	11.9
Large intestine	NCIH716	11.8
Large intestine	NCIH747	12.5
Large intestine	OUMS23	12
Large intestine	RCM1	11.7
Large intestine	RKO	12.9
Large intestine	SKCO1	11.9
Large intestine	SNU1040	11.7
Large intestine	SNU1197	12.1
Large intestine	SNU175	12.5
Large intestine	SNU283	12.7
Large intestine	SNU407	12.6
Large intestine	SNU503	12.3
Large intestine	SNU61	12.6
Large intestine	SNU81	13.1
Large intestine	SNUC1	12.3
Large intestine	SNUC2A	12
Large intestine	SNUC4	12.6
Large intestine	SNUC5	12.7
Large intestine	SW1116	12.7
Large intestine	SW1417	12.5
Large intestine	SW1463	12.5
Large intestine	SW403	12
Large intestine	SW480	12.4
Large intestine	SW48	12.6
Large intestine	SW620	12.6
Large intestine	SW837	12.3
Large intestine	SW948	12.6
Large intestine	T84	12.4
Liver	ALEXANDERCELLS	12
Liver	C3A	11.3
Liver	HEP3B217	12.5
Liver	HEPG2	11.5
Liver	HLE	11.8
Liver	HLF	11.9
Liver	HUH1	12
Liver	HUH6	12.4
Liver	HUH7	12.2
Liver	JHH1	12.2
Liver	JHH2	11.3
Liver	JHH4	12.2
Liver	JHH5	12.5
Liver	JHH6	12.4
Liver	JHH7	12.3
Liver	LI7	12.2
Liver	PLCPRF5	11.7
Liver	SKHEP1	11.7
Liver	SNU182	11.8
Liver	SNU387	11.8
Liver	SNU398	12.2
Liver	SNU423	12.1
Liver	SNU449	11.8
Liver	SNU475	12
Liver	SNU761	11.7
Liver	SNU878	11.6
Liver	SNU886	12.5
Lung	A549	12.1
Lung	ABC1	12.8
Lung	BEN	11.9
Lung	CAL12T	12.3
Lung	CALU1	12.4
Lung	CALU3	12.1
Lung	CALU6	12.5
Lung	CHAGOK1	12.3
Lung	COLO668	12.4
Lung	COLO699	12.6
Lung	CORL105	12.4
Lung	CORL23	12.4
Lung	CORL24	12
Lung	CORL279	12.8
Lung	CORL311	12.6
Lung	CORL47	12.6
Lung	CORL51	12.7
Lung	CORL88	12.9
Lung	CORL95	12.8
Lung	CPCN	12.2
Lung	DMS114	11.5
Lung	DMS153	12.3
Lung	DMS273	12.5
Lung	DMS454	12
Lung	DMS53	11.7
Lung	DMS79	11.9
Lung	DV90	11.9
Lung	EBC1	12.1
Lung	EPLC272H	12
Lung	HARA	12.5
Lung	HCC1171	12.1
Lung	HCC1195	11.3
Lung	HCC15	12.1
Lung	HCC2279	12
Lung	HCC2935	12.5
Lung	HCC33	12.2
Lung	HCC366	12.5
Lung	HCC4006	12.2
Lung	HCC44	12.5
Lung	HCC78	11.9
Lung	HCC827	12.7
Lung	HCC95	12.4
Lung	HLC1	12.7
Lung	HLFA	11.3
Lung	HS229T	11.9
Lung	HS618T	11.3
Lung	IALM	12.2
Lung	KNS62	12.2
Lung	LC1F	11.5
Lung	LC1SQSF	11.5
Lung	LCLC103H	12.2
Lung	LCLC97TM1	12.7
Lung	LK2	13
Lung	LOUNH91	12
Lung	LU65	11.9
Lung	LU99	12
Lung	LUDLU1	12
Lung	LXF289	12.6
Lung	MORCPR	12.6
Lung	NCIH1048	13
Lung	NCIH1092	12.7
Lung	NCIH1105	12.6
Lung	NCIH1155	12.2
Lung	NCIH1184	12.2
Lung	NCIH1299	12.7
Lung	NCIH1339	12.6
Lung	NCIH1341	11.9
Lung	NCIH1355	12.4
Lung	NCIH1373	11.8
Lung	NCIH1385	12
Lung	NCIH1395	11.6
Lung	NCIH1435	12.2
Lung	NCIH1436	12.6
Lung	NCIH1437	12.1
Lung	NCIH146	12.1
Lung	NCIH1563	11.6
Lung	NCIH1568	12
Lung	NCIH1573	11.2
Lung	NCIH1581	11.6
Lung	NCIH1618	12.8
Lung	NCIH1623	12.2
Lung	NCIH1648	11.5
Lung	NCIH1650	12.4
Lung	NCIH1651	11.5
Lung	NCIH1666	11.9
Lung	NCIH1693	11.3
Lung	NCIH1694	12
Lung	NCIH1703	12.5
Lung	NCIH1734	11.9
Lung	NCIH1755	12.3
Lung	NCIH1781	12.2
Lung	NCIH1792	12.3
Lung	NCIH1793	12.5
Lung	NCIH1836	11.9
Lung	NCIH1838	11
Lung	NCIH1869	12.2
Lung	NCIH1876	13.2
Lung	NCIH1915	11.4
Lung	NCIH1930	12.5
Lung	NCIH1944	12.3
Lung	NCIH1963	12.5
Lung	NCIH196	12.1
Lung	NCIH1975	12.1
Lung	NCIH2009	12.7
Lung	NCIH2023	12.1
Lung	NCIH2029	11.9
Lung	NCIH2030	10.4
Lung	NCIH2066	12.1
Lung	NCIH2081	12.8
Lung	NCIH2085	11.4
Lung	NCIH2087	11.4
Lung	NCIH209	12.6
Lung	NCIH2106	12.2
Lung	NCIH2110	12.3
Lung	NCIH211	12
Lung	NCIH2122	12.2
Lung	NCIH2126	12.3
Lung	NCIH2141	12.9
Lung	NCIH2170	12.5
Lung	NCIH2171	12.8
Lung	NCIH2172	12.5
Lung	NCIH2196	12
Lung	NCIH2227	11.8
Lung	NCIH2228	12.5
Lung	NCIH226	12.2
Lung	NCIH2286	12.7
Lung	NCIH2291	12.2
Lung	NCIH2342	11.8
Lung	NCIH2347	11.6
Lung	NCIH23	12.1
Lung	NCIH2405	11.8
Lung	NCIH2444	11.8
Lung	NCIH292	12.3
Lung	NCIH322	12.1
Lung	NCIH3255	11.7
Lung	NCIH358	12.4
Lung	NCIH441	11.6
Lung	NCIH446	12
Lung	NCIH460	12.7
Lung	NCIH510	11.9
Lung	NCIH520	12.5
Lung	NCIH522	11.6
Lung	NCIH524	12.7
Lung	NCIH526	12.6
Lung	NCIH596	12.1
Lung	NCIH647	11.8
Lung	NCIH650	11.6
Lung	NCIH661	11.1
Lung	NCIH69	12.6
Lung	NCIH727	12.3
Lung	NCIH810	12.6
Lung	NCIH82	12.4
Lung	NCIH838	12.3
Lung	NCIH841	12.1
Lung	NCIH854	11.5
Lung	NCIH889	12.5
Lung	PC14	12.6
Lung	RERFLCAD1	12
Lung	RERFLCAD2	11.6
Lung	RERFLCAI	12.4
Lung	RERFLCKJ	11.6
Lung	RERFLCMS	11.9
Lung	RERFLCSQ1	11.5
Lung	SBC5	11.9
Lung	SCLC21H	13
Lung	SHP77	12.3
Lung	SKLU1	11.9
Lung	SKMES1	11.7
Lung	SQ1	11.8
Lung	SW1271	12.7
Lung	SW1573	12.4
Lung	SW900	11.9
Lung	VMRCLCD	12.3
Lung	VMRCLCP	11.6
Oesophagus	COLO680N	12.3
Oesophagus	ECGI10	12.5
Oesophagus	KYSE140	12.4
Oesophagus	KYSE150	12.7
Oesophagus	KYSE180	12.8
Oesophagus	KYSE270	11.9
Oesophagus	KYSE30	12.4
Oesophagus	KYSE410	12.5
Oesophagus	KYSE450	12.5
Oesophagus	KYSE510	12.8
Oesophagus	KYSE520	12.5
Oesophagus	KYSE70	12.7
Oesophagus	OE19	12.6
Oesophagus	OE33	12.4
Oesophagus	TE10	11.8
Oesophagus	TE11	12.5
Oesophagus	TE14	12.2
Oesophagus	TE15	12.3
Oesophagus	TE1	12.3
Oesophagus	TE4	12.4
Oesophagus	TE5	12
Oesophagus	TE6	12.2
Oesophagus	TE8	12.8
Oesophagus	TE9	12.5
Oesophagus	TT	12.2
Ovary	59M	12.3
Ovary	A2780	12.5
Ovary	CAOV3	11.1
Ovary	CAOV4	11.7
Ovary	COLO704	12
Ovary	COV318	11.7
Ovary	COV362	12.2
Ovary	COV434	12.3
Ovary	COV504	12.1
Ovary	COV644	12.5
Ovary	EFO21	12.2
Ovary	EFO27	12.5
Ovary	ES2	12.3
Ovary	FUOV1	11.8
Ovary	HEYA8	12.6
Ovary	HS571T	10.8
Ovary	IGROV1	12.5
Ovary	JHOC5	11.3
Ovary	JHOM1	11.7
Ovary	JHOM2B	12.5
Ovary	JHOS2	12.2
Ovary	JHOS4	10.9
Ovary	KURAMOCHI	12.6
Ovary	MCAS	12.3
Ovary	NIHOVCAR3	12.5
Ovary	OAW28	12.6
Ovary	OAW42	12.1
Ovary	OC314	12.3
Ovary	OC316	12.1
Ovary	ONCODG1	12.5
Ovary	OV56	11.1
Ovary	OV7	12.4
Ovary	OV90	12.1
Ovary	OVCAR4	11.7
Ovary	OVCAR8	12.1
Ovary	OVISE	11.8
Ovary	OVK18	12.6
Ovary	OVKATE	11.9
Ovary	OVMANA	11.4
Ovary	OVSAHO	11.9
Ovary	OVTOKO	11.2
Ovary	RMGI	11.8
Ovary	RMUGS	11.9
Ovary	SKOV3	12.3
Ovary	SNU119	11.7
Ovary	SNU840	11.6
Ovary	SNU8	12
Ovary	TOV112D	12.8
Ovary	TOV21G	11.8
Ovary	TYKNU	11.6
Pancreas	ASPC1	11.6
Pancreas	BXPC3	12.4
Pancreas	CAPAN1	11.9
Pancreas	CAPAN2	11.8
Pancreas	CFPAC1	11.1
Pancreas	DANG	12.7
Pancreas	HPAC	12.3
Pancreas	HPAFII	11.5
Pancreas	HS766T	11.9
Pancreas	HUPT3	12.1
Pancreas	HUPT4	12.4
Pancreas	KCIMOH1	12.3
Pancreas	KLM1	13.1
Pancreas	KP2	12.3
Pancreas	KP3	11.6
Pancreas	KP4	12.4
Pancreas	L33	12.1
Pancreas	MIAPACA2	12.6
Pancreas	PANC0203	12.2
Pancreas	PANC0213	11.5
Pancreas	PANC0327	11.8
Pancreas	PANC0403	11.8
Pancreas	PANC0504	12
Pancreas	PANC0813	12.5
Pancreas	PANC1005	12.4
Pancreas	PANC1	11.4
Pancreas	PATU8902	12.6
Pancreas	PATU8988S	12.2
Pancreas	PATU8988T	12.7
Pancreas	PK1	12.5
Pancreas	PK45H	12.7
Pancreas	PK59	12.2
Pancreas	PL45	12.2
Pancreas	PSN1	12.5
Pancreas	QGP1	12.4
Pancreas	SNU213	11.5
Pancreas	SNU324	12.5
Pancreas	SNU410	12.2
Pancreas	SU8686	11.4
Pancreas	SUIT2	12.4
Pancreas	SW1990	11.9
Pancreas	T3M4	12.4
Pancreas	TCCPAN2	12
Pancreas	YAPC	12.9
Pleura	ACCMESO1	12.1
Pleura	DM3	11.5
Pleura	ISTMES1	11.8
Pleura	ISTMES2	12.1
Pleura	JL1	12.1
Pleura	MPP89	12.3
Pleura	MSTO211H	12.5
Pleura	NCIH2052	12.4
Pleura	NCIH2452	12.5
Pleura	NCIH28	12.4
Prostate	22RV1	12.5
Prostate	DU145	12.6
Prostate	LNCAPCLONEFGC	12
Prostate	MDAPCA2B	12
Prostate	NCIH660	12.5
Prostate	PC3	11.9
Prostate	VCAP	12.6
Salivary gland	A253	12.8
Salivary gland	YD15	12.3
Skin	A101D	11.5
Skin	A2058	12.5
Skin	A375	12.4
Skin	C32	11.6
Skin	CHL1	12.1
Skin	CJM	12.3
Skin	COLO679	12.1
Skin	COLO741	11.8
Skin	COLO783	11.8
Skin	COLO792	12.6
Skin	COLO800	11.9
Skin	COLO818	11.7
Skin	COLO829	12
Skin	COLO849	12.4
Skin	G361	12.5
Skin	GRM	12.9
Skin	HMCB	12.3
Skin	HS294T	11.6
Skin	HS600T	11.1
Skin	HS688AT	11.4
Skin	HS695T	11.6
Skin	HS839T	11.5
Skin	HS852T	11.7
Skin	HS895T	11.6
Skin	HS934T	11.6
Skin	HS936T	11.7
Skin	HS939T	11.7
Skin	HS940T	11
Skin	HS944T	12.3
Skin	HT144	12.1
Skin	IGR1	11.9
Skin	IGR37	11.9
Skin	IGR39	12.5
Skin	IPC298	11.9
Skin	K029AX	12
Skin	LOXIMVI	12.4
Skin	MALME3M	11.7
Skin	MDAMB435S	12.2
Skin	MELHO	11.9
Skin	MELJUSO	12.1
Skin	MEWO	12.6
Skin	RPMI7951	11.9
Skin	RVH421	11.5
Skin	SH4	12
Skin	SKMEL1	11.5
Skin	SKMEL24	11.2
Skin	SKMEL28	11.7
Skin	SKMEL2	12
Skin	SKMEL30	12.1
Skin	SKMEL31	11.1
Skin	SKMEL3	11.6
Skin	SKMEL5	12.3
Skin	UACC257	11.9
Skin	UACC62	11.9
Skin	WM115	11.8
Skin	WM1799	12.3
Skin	WM2664	12
Skin	WM793	12.1
Skin	WM88	11.9
Skin	WM983B	12.4
Small intestine	HUTU80	12.3
Soft tissue	A204	12.1
Soft tissue	G401	12.8
Soft tissue	G402	11.6
Soft tissue	GCT	11.7
Soft tissue	HS729	11.7
Soft tissue	HT1080	12
Soft tissue	KYM1	12.3
Soft tissue	MESSA	12.6
Soft tissue	RD	12.8
Soft tissue	RH30	12.6
Soft tissue	RH41	13.1
Soft tissue	RKN	12.2
Soft tissue	S117	11.7
Soft tissue	SJRH30	12.7
Soft tissue	SKLMS1	11.6
Soft tissue	SKUT1	11.9
Soft tissue	TE125T	11.7
Soft tissue	TE159T	11.3
Soft tissue	TE441T	13.1
Soft tissue	TE617T	12.2
Stomach	2313287	12.2
Stomach	AGS	11.9
Stomach	AZ521	12.3
Stomach	ECC10	12.7
Stomach	ECC12	11.7
Stomach	FU97	11.8
Stomach	GCIY	12.5
Stomach	GSS	12.4
Stomach	GSU	12.1
Stomach	HGC27	12.3
Stomach	HS746T	11.5
Stomach	HUG1N	11.8
Stomach	IM95	11.8
Stomach	KATOIII	12.1
Stomach	KE39	12.1
Stomach	LMSU	12
Stomach	MKN1	12.1
Stomach	MKN45	12.7
Stomach	MKN74	11.8
Stomach	MKN7	12.8
Stomach	NCCSTCK140	12.3
Stomach	NCIN87	12.6
Stomach	NUGC2	12.5
Stomach	NUGC3	13
Stomach	NUGC4	12.4
Stomach	OCUM1	12.3
Stomach	RERFGC1B	12.5
Stomach	SH10TC	12.2
Stomach	SNU16	12.1
Stomach	SNU1	12.3
Stomach	SNU216	12.5
Stomach	SNU520	12
Stomach	SNU5	12.2
Stomach	SNU601	12.8
Stomach	SNU620	12.7
Stomach	SNU668	11.8
Stomach	SNU719	12.1
Stomach	TGBC11TKB	12.5
Thyroid	8305C	12.3
Thyroid	8505C	12.8
Thyroid	BCPAP	11.8
Thyroid	BHT101	11.8
Thyroid	CAL62	12.6
Thyroid	CGTHW1	12.1
Thyroid	FTC133	12.2
Thyroid	FTC238	12.6
Thyroid	ML1	11.9
Thyroid	SW579	11.8
Thyroid	TT2609C02	12.8
Thyroid	TT	11
Upper aerodigestive tract	BHY	11.3
Upper aerodigestive tract	BICR16	12.4
Upper aerodigestive tract	BICR18	13
Upper aerodigestive tract	BICR22	12.8
Upper aerodigestive tract	BICR31	12.1
Upper aerodigestive tract	BICR56	11.7
Upper aerodigestive tract	BICR6	12.3
Upper aerodigestive tract	CAL27	12.4
Upper aerodigestive tract	CAL33	12.5
Upper aerodigestive tract	DETROIT562	12.3
Upper aerodigestive tract	FADU	12.4
Upper aerodigestive tract	HS840T	11.6
Upper aerodigestive tract	HSC2	12
Upper aerodigestive tract	HSC3	12.6
Upper aerodigestive tract	HSC4	12.1
Upper aerodigestive tract	PECAPJ15	12.5
Upper aerodigestive tract	PECAPJ34CLONEC12	12.7
Upper aerodigestive tract	PECAPJ41CLONED2	12.4
Upper aerodigestive tract	PECAPJ49	12.3
Upper aerodigestive tract	SCC15	12.5
Upper aerodigestive tract	SCC25	12.4
Upper aerodigestive tract	SCC4	11.9
Upper aerodigestive tract	SCC9	11.6
Upper aerodigestive tract	SNU1076	12.6
Upper aerodigestive tract	SNU1214	12.6
Upper aerodigestive tract	SNU46	12.6
Upper aerodigestive tract	SNU899	12
Upper aerodigestive tract	YD10B	11.9
Upper aerodigestive tract	YD38	12.9
Upper aerodigestive tract	YD8	12.3
Urinary tract	5637	12.3
Urinary tract	639V	12.6
Urinary tract	647V	12.4
Urinary tract	BC3C	12.7
Urinary tract	BFTC905	12.7
Urinary tract	CAL29	12.1
Urinary tract	HS172T	11.7
Urinary tract	HT1197	12.3
Urinary tract	HT1376	12.5
Urinary tract	J82	12.3
Urinary tract	JMSU1	12.9
Urinary tract	KMBC2	12.5
Urinary tract	KU1919	12.3
Urinary tract	RT11284	12.5
Urinary tract	RT112	12.3
Urinary tract	RT4	11.8
Urinary tract	SCABER	11.7
Urinary tract	SW1710	12.5
Urinary tract	SW780	11.4
Urinary tract	T24	12.4
Urinary tract	TCCSUP	12.8
Urinary tract	UMUC1	12.5
Urinary tract	UMUC3	11
Urinary tract	VMCUB1	12

> The Human Protein Atlas (HPA)

[ TOP ]

Tissue	Expression Level (TPM)
Adipose tissue	145.8
Adrenal gland	161.6
Appendix	272.4
Bone marrow	164
Breast	213.4
Cerebral cortex	249
Cervix, uterine	225
Colon	162
Duodenum	130.3
Endometrium	292.5
Epididymis	105.5
Esophagus	218.8
Fallopian tube	251.1
Gallbladder	237.6
Heart muscle	98.6
Kidney	166.5
Liver	83.5
Lung	193.6
Lymph node	366.1
Ovary	235.5
Pancreas	37
Parathyroid gland	258.8
Placenta	294.3
Prostate	214.4
Rectum	193
Salivary gland	60.7
Seminal vesicle	187.9
Skeletal muscle	62.5
Skin	183.3
Small intestine	149.2
Smooth muscle	242.5
Spleen	239.4
Stomach	132.2
Testis	196.4
Thyroid gland	351.9
Tonsil	289
Urinary bladder	255.4

> Text Mining based Expression

[ TOP ]

PMID	Expression	Cancer	Evidence
27705940	Overexpression	T Acute Lymphoblastic Leukemia	Here we demonstrate that both SET and c-MYC expression are frequently elevated in T-ALL cell lines and primary samples compared to healthy T cells.
27698810	Overexpression	Glioma	Positive protein expression of SET was observed in the cell nucleus, with the expression level of SET significantly higher in glioma tissues compared with normal brain tissue (P=0.001).
27517624	Overexpression	Colorectal Carcinoma	MiR-199b was found downregulated in 25% of cases, and associated with lymph metastasis (p = 0.049), presence of synchronous metastasis at diagnosis (p = 0.026) and SET overexpression (p < 0.001).
27383536	Overexpression	Ovarian Carcinoma	miR-125b expression was markedly lower in the EOC specimens. Ectopic expression of miR-125b in EOC cells significantly inhibited tumor invasion.miR-125b expression was negatively associated with both EMT and SET expression, in vivo and in vitro.
27283489	Overexpression	Acute Myeloid Leukemia	Altogether, this study opens new directions for understanding the mechanisms that lead to SET overexpression, and demonstrates that MYC, SP1, RUNX1 and GATA2 are key transcriptional regulators of SET expression in AML.
25945834	Overexpression	non-Small Cell Lung Carcinoma	In this study, we showed that SET was evidently overexpressed in human NSCLC cell lines and NSCLC tissues.
25388166	Overexpression	Colorectal Carcinoma	SET overexpression was detected in 24.8% (60 of 242) of patients with mCRC and determined significantly shorter overall (8.6 vs. 27 months; P < 0.001) and progression-free survival (7.1 vs. 13.7 months; P < 0.001), and poor response to oxaliplatin-based chemotherapy (P = 0.004).
24944693	Overexpression	Colorectal Adenocarcinoma	mRNA expression levels of SET and β-catenin were found to be elevated in 22 (70.9%) samples, while PP2A expression levels were upregulated in eight (25.8%) samples.
24927563	Overexpression	Breast Carcinoma	Here we show that SET is overexpressed in about 50-60% and CIP2A in about 90% of breast cancers.
24857208	Overexpression	Acute Myeloid Leukemia	Multivariate COX regression analysis showed SET overexpression was an independent prognostic factor for OS.
24621013	Overexpression	Alveolar soft part sarcoma	Immunohistochemistry confirmed overexpression of SET in all 15 ASPS cases examined.
23319340	altered expression	Thyroid Gland Carcinoma	Furthermore, differential expression of amyloid beta A4 protein, AXL, heterogeneous nuclear ribonucleoprotein K, phosphoglycerate kinase 1, pyruvate kinase muscle isozyme M2, and SET was observed in TC tissues compared to benign nodules.
23180565	Overexpression	Lung Carcinoma	Because I2PP2A/SET was found overexpressed, whereas ceramide was downregulated in lung tumours, a sphingolipid analogue drug, FTY720, was identified to mimick ceramide for binding and targeting I2PP2A/SET, leading to PP2A reactivation, lung cancer cell death, and tumour suppression in vivo.
23131782	Overexpression	canine Lymphoma	We observed SET protein levels increased in multiple canine lymphoma cell lines compared with primary peripheral blood cells.
23106910	Overexpression	Head and Neck Squamous Cell Carcinoma	Cells with SET overexpression (HEK293/SET, HN13 and HN12) showed lower ALDH2 and GSTP1 mRNA levels and trichostatinA increased them (real-time PCR).
23023584	Overexpression	Colon Carcinoma	In addition, the mRNA expression of SET and E-cadherin was upregulated in the SW480-FBXL20 and SW620-FBXL20 cells, whereas that of β-catenin, c-Myc, cyclinD1, p53 and PP2A was downregulated.
22739068	Overexpression	Head and Neck Squamous Cell Carcinoma	SET levels were up-regulated in 97% tumor tissue samples and in HNSCC cell lineages.
22677993	Overexpression	B Acute Lymphoblastic Leukemia; T Acute Lymphoblastic Leukemia	We showed that SET expression was significantly upregulated in 96.5% of B-acute lymphoblastic leukemia (28 of 29; 16.6 fold) and 93% of T-acute lymphoblastic leukemia (28 of 30; 47.6 fold) patients.
22133779	Overexpression	Acute Myeloid Leukemia	We quantified SET expression by real time reverse transcriptase polymerase chain reaction in 214 acute myeloid leukemia patients at diagnosis. SET overexpression was found in 60/214 patients, for a prevalence of 28%.
22082227	Overexpression	Hepatocellular Carcinoma	The SET complex, a central component in the GzmA pathway, was significantly up-regulated in HCC tissue.
21843667	Overexpression	Colorectal Carcinoma	We have also identified many previously unknown changes including overexpression of ACY1, HSC70, HnRNP I, HnRNP A3, SET, ANP32A and TUFM in CRC, which have been further verified by western blotting and immunohistochemistry.
28677734	Overexpression	Gastric Carcinoma	Taken together, our results suggested that SET overexpression is associated with GC progression, and it might be a potential diagnostic marker for GC, thereby a possible target for GC drug development.
27517624	Overexpression	Colorectal Carcinoma	We show here miR-199b downregulation in 4 out of 5 CRC SET-overexpressing cell lines and its inverse correlation with SET overexpression in CRC patients.

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Somatic copy number alteration in primary tomur tissue

> The Cancer Genome Atlas (TCGA)

[ TOP ]

Correlation between expression and SCNA as well as percentage of patients in different status.

Cancer	Full Name	# Sample	R	P	% Loss	% Neutral	% Gain	Status
BLCA	Bladder urothelial carcinoma	404	0.716	9.89e-65	40.6	44.8	14.6	Loss
BRCA	Breast invasive carcinoma	1075	0.441	1.85e-52	26.3	59.7	14	Neutral
CESC	Cervical and endocervical cancers	292	0.567	2.79e-26	17.8	62.7	19.5	Neutral
COAD	Colon adenocarcinoma	449	0.28	1.58e-09	12.7	72.8	14.5	Neutral
ESCA	Esophageal carcinoma	183	0.633	6.79e-22	29.5	40.4	30.1	Neutral
GBM	Glioblastoma multiforme	147	0.674	8.94e-21	15	67.3	17.7	Neutral
HNSC	Head and Neck squamous cell carcinoma	514	0.665	5.25e-67	12.5	53.9	33.7	Gain
KIRC	Kidney renal clear cell carcinoma	525	0.578	4.02e-48	28.8	68.8	2.5	Neutral
KIRP	Kidney renal papillary cell carcinoma	288	0.445	2.09e-15	11.1	87.8	1	Neutral
LAML	Acute Myeloid Leukemia	166	0.112	0.152	0.6	98.2	1.2	Neutral
LGG	Brain Lower Grade Glioma	513	0.48	6.72e-31	9.4	83.4	7.2	Neutral
LIHC	Liver hepatocellular carcinoma	364	0.59	1.7e-35	30.5	60.7	8.8	Neutral
LUAD	Lung adenocarcinoma	512	0.526	9.89e-38	43.6	46.1	10.4	Loss
LUSC	Lung squamous cell carcinoma	498	0.626	1.55e-55	47.4	32.9	19.7	Loss
OV	Ovarian serous cystadenocarcinoma	300	0.722	1.4e-49	57	30	13	Loss
PAAD	Pancreatic adenocarcinoma	177	0.335	5.17e-06	23.2	70.6	6.2	Neutral
PCPG	Pheochromocytoma and Paraganglioma	162	0.448	2.31e-09	6.2	92	1.9	Neutral
PRAD	Prostate adenocarcinoma	491	0.475	6.07e-29	2.2	85.5	12.2	Neutral
READ	Rectum adenocarcinoma	164	0.338	9.41e-06	18.9	59.8	21.3	Neutral
SARC	Sarcoma	255	0.555	5.38e-22	18.8	51.8	29.4	Neutral
SKCM	Skin Cutaneous Melanoma	367	0.617	6.66e-40	46.3	45.8	7.9	Loss
STAD	Stomach adenocarcinoma	413	0.555	8.9e-35	19.9	56.2	24	Neutral
TGCT	Testicular Germ Cell Tumors	150	0.356	7.9e-06	40.7	49.3	10	Loss
THCA	Thyroid carcinoma	497	0.436	1.81e-24	5.6	93.4	1	Neutral
THYM	Thymoma	119	0.139	0.133	2.5	88.2	9.2	Neutral
UCEC	Uterine Corpus Endometrial Carcinoma	537	0.383	3.06e-20	23.5	72.1	4.5	Neutral

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Methylation level in the promoter region of CR

> Methylation level in the promoter region of CR

[ TOP ]

Correlation between expression and methylation as well as differential methylation analysis.

Cancer	Full Name	R	P	# N	# T	Delta beta (T vs N)	P value (T vs N)	Status
BLCA	Bladder urothelial carcinoma	-0.226	2.82e-06	17	408	-0.069	0.000154	NS/NA
BRCA	Breast invasive carcinoma	-0.295	7.98e-19	83	785	-0.009	6.05e-06	NS/NA
CESC	Cervical and endocervical cancers	-0.066	0.247	3	306	NA	NA	NS/NA
COAD	Colon adenocarcinoma	-0.282	3.91e-07	19	297	-0.004	0.0778	NS/NA
ESCA	Esophageal carcinoma	-0.106	0.142	9	185	NA	NA	NS/NA
GBM	Glioblastoma multiforme	-0.097	0.44	1	64	NA	NA	NS/NA
HNSC	Head and Neck squamous cell carcinoma	-0.152	0.00039	20	522	-0.007	0.378	NS/NA
KIRC	Kidney renal clear cell carcinoma	0.037	0.493	24	319	0.002	0.0567	NS/NA
KIRP	Kidney renal papillary cell carcinoma	-0.219	0.000139	23	275	-0.03	0.0294	NS/NA
LAML	Acute Myeloid Leukemia	-0.108	0.163	0	170	NA	NA	NS/NA
LGG	Brain Lower Grade Glioma	0.037	0.399	0	530	NA	NA	NS/NA
LIHC	Liver hepatocellular carcinoma	-0.034	0.495	41	373	-0.041	1.16e-05	NS/NA
LUAD	Lung adenocarcinoma	-0.095	0.038	21	456	0.001	0.189	NS/NA
LUSC	Lung squamous cell carcinoma	0.001	0.983	8	370	NA	NA	NS/NA
OV	Ovarian serous cystadenocarcinoma	-0.55	0.133	0	9	NA	NA	NS/NA
PAAD	Pancreatic adenocarcinoma	-0.114	0.124	4	179	NA	NA	NS/NA
PCPG	Pheochromocytoma and Paraganglioma	0.109	0.136	3	184	NA	NA	NS/NA
PRAD	Prostate adenocarcinoma	-0.229	9.99e-08	35	498	-0.007	0.0282	NS/NA
READ	Rectum adenocarcinoma	-0.137	0.172	2	99	NA	NA	NS/NA
SARC	Sarcoma	-0.111	0.0731	0	263	NA	NA	NS/NA
SKCM	Skin Cutaneous Melanoma	-0.072	0.12	1	471	NA	NA	NS/NA
STAD	Stomach adenocarcinoma	-0.383	2.37e-14	0	372	NA	NA	NS/NA
TGCT	Testicular Germ Cell Tumors	-0.244	0.00223	0	156	NA	NA	NS/NA
THCA	Thyroid carcinoma	-0.135	0.00135	50	509	-0.009	6.56e-05	NS/NA
THYM	Thymoma	-0.266	0.00311	2	120	NA	NA	NS/NA
UCEC	Uterine Corpus Endometrial Carcinoma	-0.074	0.111	34	431	-0.019	0.0159	NS/NA

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Primary tumor tissue from TCGA > Normal tumor tissue from HPA

>The Cancer Genome Atlas (TCGA) [ TOP ]
There is no record.

> The Human Protein Atlas (HPA)

[ TOP ]

Tissue	Level	Level Name
Adrenal gland	3	High
Appendix	3	High
Bone marrow	3	High
Breast	3	High
Bronchus	3	High
Caudate	3	High
Cerebellum	3	High
Cerebral cortex	2	Medium
Cervix, uterine	3	High
Colon	3	High
Duodenum	3	High
Endometrium	3	High
Epididymis	3	High
Esophagus	3	High
Fallopian tube	3	High
Gallbladder	3	High
Heart muscle	1	Low
Hippocampus	3	High
Kidney	3	High
Liver	2	Medium
Lung	2	Medium
Lymph node	3	High
Nasopharynx	3	High
Oral mucosa	3	High
Ovary	2	Medium
Pancreas	3	High
Parathyroid gland	3	High
Placenta	3	High
Prostate	2	Medium
Rectum	3	High
Salivary gland	3	High
Seminal vesicle	3	High
Skeletal muscle	2	Medium
Skin	3	High
Small intestine	3	High
Smooth muscle	2	Medium
Soft tissue	2	Medium
Spleen	3	High
Stomach	3	High
Testis	3	High
Thyroid gland	3	High
Tonsil	3	High
Urinary bladder	3	High
Vagina	3	High

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Association between expresson and subtype > Overall survival analysis based on expression > Association between expresson and stage > Association between expresson and grade

> Subtype

[ TOP ]

Association between expresson and subtype.

Cancer	Full Name	# Patients	P Value (Kruskal-Wallis)	Association	Source
BLCA	Bladder urothelial carcinoma	128	0.287	NS	24476821
BRCA	Breast invasive carcinoma	521	1.82e-09	Significant	23000897
COAD	Colon adenocarcinoma	149	0.128	NS	22810696
GBM	Glioblastoma multiforme	157	0.0178	Significant	26824661
HNSC	Head and Neck squamous cell carcinoma	279	6.46e-06	Significant	25631445
KIRP	Kidney renal papillary cell carcinoma	161	0.0435	Significant	26536169
LGG	Brain Lower Grade Glioma	513	0.00153	Significant	26824661
LUAD	Lung adenocarcinoma	230	1.36e-06	Significant	25079552
LUSC	Lung squamous cell carcinoma	178	2.43e-13	Significant	22960745
OV	Ovarian serous cystadenocarcinoma	287	0.114	NS	21720365
PRAD	Prostate adenocarcinoma	333	1.25e-06	Significant	26544944
READ	Rectum adenocarcinoma	67	0.206	NS	22810696
SKCM	Skin Cutaneous Melanoma	315	0.000248	Significant	26091043
STAD	Stomach adenocarcinoma	277	5.96e-11	Significant	25079317
THCA	Thyroid carcinoma	391	9.93e-12	Significant	25417114
UCEC	Uterine Corpus Endometrial Carcinoma	232	0.792	NS	23636398

> Overall survival

[ TOP ]

Overall survival analysis based on expression.

Cancer	Full Name	# Patients	Hazard Ratio	P Value (Log Rank Test)	Association
BLCA	Bladder urothelial carcinoma	405	1.233	0.342	NS
BRCA	Breast invasive carcinoma	1079	1.172	0.511	NS
CESC	Cervical and endocervical cancers	291	1.083	0.83	NS
COAD	Colon adenocarcinoma	439	0.893	0.707	NS
ESCA	Esophageal carcinoma	184	0.806	0.517	NS
GBM	Glioblastoma multiforme	158	0.779	0.314	NS
HNSC	Head and Neck squamous cell carcinoma	518	1.659	0.0076	Shorter
KIRC	Kidney renal clear cell carcinoma	531	0.708	0.0923	NS
KIRP	Kidney renal papillary cell carcinoma	287	1.501	0.363	NS
LAML	Acute Myeloid Leukemia	149	0.741	0.309	NS
LGG	Brain Lower Grade Glioma	511	0.665	0.0855	NS
LIHC	Liver hepatocellular carcinoma	365	1.558	0.0541	NS
LUAD	Lung adenocarcinoma	502	1.548	0.0395	Shorter
LUSC	Lung squamous cell carcinoma	494	0.905	0.612	NS
OV	Ovarian serous cystadenocarcinoma	303	1.136	0.542	NS
PAAD	Pancreatic adenocarcinoma	177	1.644	0.109	NS
PCPG	Pheochromocytoma and Paraganglioma	179	1.534	0.732	NS
PRAD	Prostate adenocarcinoma	497	1.03	0.971	NS
READ	Rectum adenocarcinoma	159	0.755	0.612	NS
SARC	Sarcoma	259	1.755	0.0624	NS
SKCM	Skin Cutaneous Melanoma	459	1.285	0.177	NS
STAD	Stomach adenocarcinoma	388	0.811	0.341	NS
TGCT	Testicular Germ Cell Tumors	134	946949227.087	0.48	NS
THCA	Thyroid carcinoma	500	0.719	0.642	NS
THYM	Thymoma	119	0	0.0253	Longer
UCEC	Uterine Corpus Endometrial Carcinoma	543	1.2	0.537	NS

> Stage

[ TOP ]

Association between expresson and stage.

Cancer	Full Name	# Patients	R Value (Spearman)	P Value (Spearman)	Association
BLCA	Bladder urothelial carcinoma	406	0.022	0.656	NS
BRCA	Breast invasive carcinoma	1071	-0.006	0.857	NS
CESC	Cervical and endocervical cancers	167	-0.18	0.02	Lower
COAD	Colon adenocarcinoma	445	-0.066	0.167	NS
ESCA	Esophageal carcinoma	162	-0.039	0.619	NS
HNSC	Head and Neck squamous cell carcinoma	448	0.141	0.00281	Higher
KIRC	Kidney renal clear cell carcinoma	531	-0.087	0.0461	Lower
KIRP	Kidney renal papillary cell carcinoma	260	0.162	0.00894	Higher
LIHC	Liver hepatocellular carcinoma	347	0.127	0.0179	Higher
LUAD	Lung adenocarcinoma	507	0.092	0.0394	Higher
LUSC	Lung squamous cell carcinoma	497	0.073	0.106	NS
OV	Ovarian serous cystadenocarcinoma	302	-0.011	0.847	NS
PAAD	Pancreatic adenocarcinoma	176	-0.064	0.397	NS
READ	Rectum adenocarcinoma	156	0.083	0.302	NS
SKCM	Skin Cutaneous Melanoma	410	-0.101	0.0417	Lower
STAD	Stomach adenocarcinoma	392	-0.009	0.863	NS
TGCT	Testicular Germ Cell Tumors	81	0.282	0.0109	Higher
THCA	Thyroid carcinoma	499	0.02	0.651	NS
UCEC	Uterine Corpus Endometrial Carcinoma	501	0.026	0.564	NS

> Grade

[ TOP ]

Association between expresson and grade.

Cancer	Full Name	# Patients	R Value (Spearman)	P Value (Spearman)	Association
CESC	Cervical and endocervical cancers	272	0.12	0.0476	Higher
HNSC	Head and Neck squamous cell carcinoma	498	0.074	0.0979	NS
KIRC	Kidney renal clear cell carcinoma	525	-0.149	0.000601	Lower
LGG	Brain Lower Grade Glioma	514	0.087	0.0493	Higher
LIHC	Liver hepatocellular carcinoma	366	0.183	0.000433	Higher
OV	Ovarian serous cystadenocarcinoma	296	0.015	0.796	NS
PAAD	Pancreatic adenocarcinoma	176	0.061	0.424	NS
STAD	Stomach adenocarcinoma	406	-0.067	0.176	NS
UCEC	Uterine Corpus Endometrial Carcinoma	534	0.212	7.93e-07	Higher

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Targets inferred by reverse engineering method > Targets identified by ChIP-seq data

> Targets inferred by reverse engineering method [ TOP ]

> Targets identified by ChIP-seq data [ TOP ]

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Drugs from DrugBank database

> Drugs from DrugBank database [ TOP ]
There is no record for SET.

Summary
Symbol	SET
Name	SET nuclear proto-oncogene
Aliases	PHAPII; 2PP2A; IPP2A2; protein phosphatase type 2A inhibitor; Template-Activating Factor-I, chromatin remode ......
Location	9q34.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Cancer Gene Databases	ONGene (Oncogene) , TSGene (Tumor suppressor gene) , NCG (Network of Cancer Genes)
Content	> Protein-Protein Interaction Network > miRNA Regulatory Relationship > Interactions from Text Mining

> Protein-Protein Interaction Network [ TOP ]

> miRNA Regulatory Relationship [ TOP ]

> Interactions from Text Mining

[ TOP ]

PMID	Cancer	Hierarchy	Gene	Relation to CR	Evidence
27698810	Glioma	downstream	Bcl-2; Bax; caspase-3	Positive regulation; negative regulation; negative regulation	Thus, the current data suggests that SET may regulate the proliferation and apoptosis of glioblastoma cells by upregulating Bcl-2, and downregulating Bax and caspase-3.
27517624	Colorectal Carcinoma	upstream	miR199b	negative regulation	We show here miR-199b downregulation in 4 out of 5 CRC SET-overexpressing cell lines and its inverse correlation with SET overexpression in CRC patients.
27383536	Ovarian Carcinoma	upstream	miR-125b	negative regulation	miR-125b expression was markedly lower in the EOC specimens. Ectopic expression of miR-125b in EOC cells significantly inhibited tumor invasion.miR-125b expression was negatively associated with both EMT and SET expression, in vivo and in vitro.
27283489	Acute Myeloid Leukemia	downstream	MYC; SP1; RUNX1; GATA2	Positive regulation	Altogether, this study opens new directions for understanding the mechanisms that lead to SET overexpression, and demonstrates that MYC, SP1, RUNX1 and GATA2 are key transcriptional regulators of SET expression in AML
24944693	Colorectal Adenocarcinoma	downstream	PP2A; c-Myc; β-catenin; E-cadherin; p53	Positive regulation; positive regulation; negative regulation; negative regulation; negative regulation	In addition, the knockdown of SET mRNA expression caused the upregulation of PP2A and c-Myc in the two cell lines, whereas β-catenin, E-cadherin and p53 mRNA expression was downregulated.
23210573	Acute Lymphoblastic Leukemia	partner	NUP214; HOX	Fusion; correlation	Our RT-nPCR assay had a positive detection rate of 35.15% (90/256) for the 10 fusion genes. BCR-ABL1, FUS-ERG, MLL-AF4, ETV6-RUNX1, E2A-PBX1, dupMLL, MLL-AF10, MLL-ENL, SET-NUP214 and SIL-TAL1 were detected in 36 (14.06%), 14 (5.47%), 14 (5.47%), four (1.56%), four (1.56%), five (1.95%), four (1.56%), two (0.78%), two (0.78%) and five patients (1.95%), respectively. JAK2 and IKZF1 mutations were commonly detected in patients with BCR-ABL1 ALL, and HOX overexpression was highly correlated with MLL fusions and SET-NUP214
23180565	Lung Carcinoma	downstream	FTY720	Negative regulation	Accordingly, while molecular targeting of I2PP2A/SET by stable knockdown prevented further tumour suppression by FTY720, reconstitution of WT-I2PP2A/SET expression restored this process.
23114116	T Acute Lymphoblastic Leukemia	partner	NUP214	Fusion	The results showed that 6 out of 58 T-ALL cases (10.3%) were detected to have the SET-NUP214 fusion gene by RT-PCR.
23106910	Head and Neck Squamous Cell Carcinoma	downstream	ALDH2; GSTP1	Negative regulation	Cells with SET overexpression (HEK293/SET, HN13 and HN12) showed lower ALDH2 and GSTP1 mRNA levels and trichostatinA increased them (real-time PCR).
22169284	Leukemia; Lymphoma	partner	NUP214	Fusion	The purpose of this study was to analyze the gene rearrangement pattern of immunoglobulin and T-cell receptor (Ig/TR) and its clinical characteristics in three children with SET-NUP214 fusion gene positive leukemia/lymphoma. The transcript of SET-NUP214 fusion gene was detected by RT-nested PCR.
22133779	Acute Myeloid Leukemia	upstream	EVI1	Regulation	These findings suggest that SET overexpression is a key mechanism in the inhibition of PP2A in acute myeloid leukemia, and that EVI1 overexpression contributes to the deregulation of SET.
22075511	T Acute Lymphoblastic Leukemia	partner	NUP-214	Rearrangement	Using multiplex reverse transcriptase-polymerase chain reaction analysis, we detected a cryptic SET-NUP214 rearrangement in our patient.
21880637	T Acute Lymphoblastic Leukemia	partner	NUP-214	Fusion	NOTCH1 mutations, FBXW7 mutations, WT1 mutations, JAK1 mutations, SIL-TAL1 fusions, SET-NUP214 fusions and CALM-AF10 fusions were present in 44/96 (45.8%), 9/96 (9.4%), 4/96 (4.1%), 3/49 (6.1%), 9/48 (18.8%), 3/48 (6.3%) and 0/48 (0%) of patients, respectively.
21720744	T Acute Lymphoblastic Leukemia	partner	NUP214	Rearrangement	Four cases (10%) of SET-NUP214 translocation were identified in our study.
20682390	acute undifferentiated Leukemia	partner	NUP214	Fusion	Herein we present a novel case of acute undifferentiated leukemia with SET-NUP214 rearrangement due to the cryptic deletion of the 9q34 region producing two different types of fusion transcripts by alternative splicing and molecular characterization of the fusion transcripts by fluorescence in situ hybridization, reverse transcriptase-polymerase chain reaction, and array comparative genomic hybridization analyses.
20494936	Acute Lymphoblastic Leukemia	partner	NUP214	Fusion	We demonstrated that high expression of miR-196b is not unique to MLL-rearranged acute lymphoblastic leukemia but also occurs in patients with T-cell acute lymphoblastic leukemia patients carrying CALM-AF10, SET-NUP214 and inversion of chromosome 7.
20417863	B Acute Lymphoblastic Leukemia	partner	NUP214	Fusion	The smallest deletion resulted in the likely juxtaposition of the SET and NUP214 genes.
27517624	Colorectal Carcinoma	upstream	miR-199b	Negative regulation	Altogether, our results show that miR-199b is a tumor suppressor whose downregulation independently determines worse outcome and emerges as a potential contributing mechanism to inhibit PP2A via SET overexpression in a subgroup of mCRC patients.